U.S. Oral Solid Dosage CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Tablets, Capsules, Powders), By Mechanism (Immediate, Delayed), By Drug Potency, By End-use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Segment Definitions
                        1.2.1. Product
                        1.2.2. Mechanism
                        1.2.3. Technology
                        1.2.4. Drug Potency
                        1.2.5. End use
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased Database
                        1.4.2. GVR’s Internal Database
                        1.4.3. Secondary Sources
                        1.4.4. Primary Research
                    1.5. Information Or Data Analysis
                        1.5.1. Data Analysis Models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity Flow Analysis
                        1.7.2. Top-Down Analysis
                        1.7.3. Botton-Up Approach
                        1.7.4. Multivariate Analysis
                    1.8. List of Secondary Sources
                    1.9. List of Abbreviations
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Oral Solid Dosage CDMO Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. Increasing Demand for One-Stop-Shop CMOs
                            3.2.1.2. Growing Demand for Generic and Specialty Oral Solid Drugs
                            3.2.1.3. Expansion of Outsourced Pharmaceutical Manufacturing
                            3.2.1.4. Technological Advancements in Formulation and Process Development
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Strict Approval Criteria by Regulatory Authorities
                            3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
                            3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
                    3.3. Technology Landscape
                    3.4. Pricing Model Analysis
                    3.5. Tariff Impact Analysis
                    3.6. Value Chain Analysis
                        3.6.1. Supply Trends
                        3.6.2. Demand Trends
                    3.7. Market Analysis Tools
                        3.7.1. Porter’s Five Force Analysis
                        3.7.2. PESTEL by SWOT Analysis
Chapter 4. U.S. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis
                    4.1. U.S. Oral Solid Dosage CDMO Market Segment Dashboard
                    4.2. U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
                    4.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
                    4.4. Tablets
                        4.4.1. Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.2. Compressed Tablets
                            4.4.2.1. Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.3. Orally Disintegrating Tablets (ODT)
                            4.4.3.1. Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.4. Chewable Tablets
                            4.4.4.1. Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.5. Bi-layer or Tri-layer Tablets
                            4.4.5.1. Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.6. Sublingual or Buccal Tablets
                            4.4.6.1. Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.4.7. Others
                            4.4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Capsules
                        4.5.1. Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.5.2. Hard Gelatin Capsules
                            4.5.2.1. Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.5.3. Soft Gelatin Capsules
                            4.5.3.1. Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Powder
                        4.6.1. Powder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.7. Granules
                        4.7.1. Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.8. Others
                        4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis
                    5.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
                    5.2. U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
                    5.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
                    5.4. Immediate Release
                        5.4.1. Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Delayed Release
                        5.5.1. Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.6. Controlled Release
                        5.6.1. Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Oral Solid Dosage CDMO Market: Technology Estimates & Trend Analysis
                    6.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
                    6.2. U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
                    6.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
                    6.4. Granulation Technologies
                        6.4.1. Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Compression Technologies
                        6.5.1. Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.6. Encapsulation Technologies
                        6.6.1. Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.7. Coating Technologies
                        6.7.1. Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.8. Continuous Manufacturing Technologies
                        6.8.1. Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.9. Others
                        6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis
                    7.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
                    7.2. U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
                    7.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2021 to 2033 (USD Million)
                    7.4. High Potent Drugs
                        7.4.1. High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Moderate Potent Drugs
                        7.5.1. Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Low Potent Drugs
                        7.6.1. Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. U.S. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis
                    8.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
                    8.2. U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
                    8.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
                    8.4. Large Size Companies
                        8.4.1. Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    8.5. Medium & Small Size Companies
                        8.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    8.6. Others
                        8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Key Participant Categorization
                        9.1.1. Market Leaders
                        9.1.2. Emerging Players
                    9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
                    9.3. Company Profiles
                        9.3.1. Lonza
                            9.3.1.1. Company Overview
                            9.3.1.2. Financial Performance
                            9.3.1.3. Service Benchmarking
                            9.3.1.4. Strategic Initiatives
                        9.3.2. Thermo Fisher Scientific Inc.
                            9.3.2.1. Company Overview
                            9.3.2.2. Financial Performance
                            9.3.2.3. Service Benchmarking
                            9.3.2.4. Strategic Initiatives
                        9.3.3. Cambrex Corporation
                            9.3.3.1. Company Overview
                            9.3.3.2. Financial Performance
                            9.3.3.3. Service Benchmarking
                            9.3.3.4. Strategic Initiatives
                        9.3.4. Catalent Inc.
                            9.3.4.1. Company Overview
                            9.3.4.2. Financial Performance
                            9.3.4.3. Service Benchmarking
                            9.3.4.4. Strategic Initiatives
                        9.3.5. Siegfried Holding AG
                            9.3.5.1. Company Overview
                            9.3.5.2. Financial Performance
                            9.3.5.3. Service Benchmarking
                            9.3.5.4. Strategic Initiatives
                        9.3.6. Recipharm AB
                            9.3.6.1. Company Overview
                            9.3.6.2. Financial Performance
                            9.3.6.3. Service Benchmarking
                            9.3.6.4. Strategic Initiatives
                        9.3.7. CordenPharma International
                            9.3.7.1. Company Overview
                            9.3.7.2. Financial Performance
                            9.3.7.3. Service Benchmarking
                            9.3.7.4. Strategic Initiatives
                        9.3.8. Boehringer Ingelheim
                            9.3.8.1. Company Overview
                            9.3.8.2. Financial Performance
                            9.3.8.3. Service Benchmarking
                            9.3.8.4. Strategic Initiatives
                        9.3.9. Piramal Pharma Solutions
                            9.3.9.1. Company Overview
                            9.3.9.2. Financial Performance
                            9.3.9.3. Service Benchmarking
                            9.3.9.4. Strategic Initiatives
                        9.3.10. Aenova Group
                            9.3.10.1. Company Overview
                            9.3.10.2. Financial Performance
                            9.3.10.3. Service Benchmarking
                            9.3.10.4. Strategic Initiatives
                        9.3.11. Almac Group
                            9.3.11.1. Company Overview
                            9.3.11.2. Financial Performance
                            9.3.11.3. Service Benchmarking
                            9.3.11.4. Strategic Initiatives
                        9.3.12. Jubilant Pharmova Limited
                            9.3.12.1. Company Overview
                            9.3.12.2. Financial Performance
                            9.3.12.3. Service Benchmarking
                            9.3.12.4. Strategic Initiatives
                        9.3.13. AbbVie Contract Manufacturing
                            9.3.13.1. Company Overview
                            9.3.13.2. Financial Performance
                            9.3.13.3. Service Benchmarking
                            9.3.13.4. Strategic Initiatives
                        9.3.14. Quotient Sciences
                            9.3.14.1. Company Overview
                            9.3.14.2. Financial Performance
                            9.3.14.3. Service Benchmarking
                            9.3.14.4. Strategic Initiatives
                        9.3.15. SPI Pharma
                            9.3.15.1. Company Overview
                            9.3.15.2. Financial Performance
                            9.3.15.3. Service Benchmarking
                            9.3.15.4. Strategic Initiatives
                        9.3.16. DPT Laboratories Ltd.
                            9.3.16.1. Company Overview
                            9.3.16.2. Financial Performance
                            9.3.16.3. Service Benchmarking
                            9.3.16.4. Strategic Initiatives
                        9.3.17. Alcami Corporation
                            9.3.17.1. Company Overview
                            9.3.17.2. Financial Performance
                            9.3.17.3. Service Benchmarking
                            9.3.17.4. Strategic Initiatives

List of Tables

Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
Table 4. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Mechanism, 2021 - 2033 (USD Million)
Table 5. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Drug Potency, 2021 - 2033 (USD Million)
Table 6. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD model sizing & forecasting
Fig. 9 Bottom-up approach
Fig. 10 Market snapshot
Fig. 11 Segment snapshot 1
Fig. 12 Segment snapshot 2
Fig. 13 Competitive landscape snapshot
Fig. 14 Parent market outlook, 2024 (USD Billion)
Fig. 15 Ancillary market outlook, 2024 (USD Billion)
Fig. 16 U.S. Oral Solid Dosage CDMO Market Dynamics
Fig. 17 Porter’s five forces analysis
Fig. 18 PESTEL analysis
Fig. 19 U.S. Oral Solid Dosage CDMO Market: Product Outlook And Key Takeaways
Fig. 20 U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
Fig. 21 Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 22 Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 23 Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 24 Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 25 Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 26 Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 27 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 28 Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 29 Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 30 Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 31 Powders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 32 Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 34 U.S. Oral Solid Dosage CDMO Market: Mechanism Outlook And Key Takeaways
Fig. 35 U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
Fig. 36 Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 37 Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 38 Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 39 U.S. Oral Solid Dosage CDMO Market: Technology Outlook And Key Takeaways
Fig. 40 U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
Fig. 41 Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 42 Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 43 Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 44 Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 45 Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 46 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 47 U.S. Oral Solid Dosage CDMO Market: Drug Potency Outlook And Key Takeaways
Fig. 48 U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
Fig. 49 High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 50 Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 51 Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 52 U.S. Oral Solid Dosage CDMO Market: End Use Outlook And Key Takeaways
Fig. 53 U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
Fig. 54 Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 55 Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 56 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)